publication . Other literature type . Article . 2017

Thiazolidinediones and the pyruvate carrier

Patrick A. Vigueira; Kyle S. McCommis; Wesley T. Hodges; George G. Schweitzer; Serena L. Cole; Lalita Oonthonpan; Eric B. Taylor; William G. McDonald; Rolf F. Kletzien; Jerry R. Colca; ...
Open Access English
  • Published: 10 Jul 2017
Abstract
Rosiglitazone and pioglitazone are thiazolidinedione (TZD) compounds that have been used clinically as insulin-sensitizing drugs and are generally believed to mediate their effects via activation of the peroxisome proliferator-activated receptor γ (PPARγ). Recent work has shown that it is possible to synthesize TZD compounds with potent insulin-sensitizing effects and markedly-diminished affinity for PPARγ. Both clinically-used TZDs and investigational PPARγ-sparing TZDs, such as MSDC-0602, interact with the mitochondrial pyruvate carrier (MPC) and inhibit its activity. Two proteins, MPC1 and MPC2, comprise the MPC complex. Herein, we used mice expressing a hypo...
Subjects
Medical Subject Headings: endocrine system diseases
free text keywords: Article, Physiology, Rosiglitazone, medicine.drug, medicine, Mitochondrion, Adipocyte, chemistry.chemical_compound, chemistry, Insulin resistance, medicine.disease, Mitochondrial pyruvate carrier 2, Endocrinology, medicine.medical_specialty, Internal medicine, Pioglitazone, Adipose tissue, Thiazolidinedione, medicine.drug_class, Biology
Powered by OpenAIRE Open Research Graph
Any information missing or wrong?Report an Issue
publication . Other literature type . Article . 2017

Thiazolidinediones and the pyruvate carrier

Patrick A. Vigueira; Kyle S. McCommis; Wesley T. Hodges; George G. Schweitzer; Serena L. Cole; Lalita Oonthonpan; Eric B. Taylor; William G. McDonald; Rolf F. Kletzien; Jerry R. Colca; ...